Wisepowder has a full range of raw materials of Aging& Antiaging , and has a total quality management system.

Showing 1–8 of 19 results

1 2 3

Aging& Antiaging(Anti-aging)

Aging is something we all do but understand very little about. Your brain undergoes changes as you age that may have minor effects on your memory or thinking skills.It’s easy to make a list of all the changes that come with age — memory loss, wrinkles, muscle loss.
Antiaging(anti-aging) can be a difficult topic to address: a war is currently fought over the meaning of the term in research and medicine, and as a brand for products in an energetic and often fraudulent
Antiaging(Anti-aging) now has a number of quite different common meanings and connotations.
-In the scientific community anti-aging(antiaging) research refers exclusively to slowing, preventing, or reversing the aging process. While the future is looking very promising, there is presently no proven and available medical technology that slows or reverses aging in humans.
-In the medical and reputable business community, anti-aging medicine means the early detection, prevention, and treatment of age-related diseases. This is quite different from tackling the aging process itself, and a wide array of strategies and therapies are currently available. For example Alzheimer’s treatment, disease which is relate to aging.
-In the wider business community – which includes a great many fraudulent or frivolous ventures – anti-aging is a valuable brand and a demonstrated way to increase sales.

Antiaging powder application

In this trend, anti-aging products are becoming more and more popular. Antiaging powder application include:
-Skin care products
-Nutritional health products
-Functional beverages
-Pharmaceutical product
Aging&Alzheimer’s treatment
Dementia becomes more common with age.About 3% of people between the ages of 65 and 74, 19% between 75 and 84, and nearly half of those over 85 years of age have dementia.The spectrum ranges from mild cognitive impairment to the neurodegenerative diseases of Alzheimer’s disease, cerebrovascular disease, Parkinson’s disease and Lou Gehrig’s disease.
Aging is the main risk factor for Alzheimer’s disease. Alzheimer’s is a type of dementia that causes problems with memory, thinking and behavior. Alzheimer’s symptoms usually develop slowly and get worse over time, becoming severe enough to interfere with daily tasks. “We know that age is the single greatest contributing factor to Alzheimer’s, so it is not surprising that we found a drug target that’s also been implicated in aging,”
The FDA has also approved such as Namzaric, a combination of Namenda(memantine) and Aricept, for the treatment of moderate to severe Alzheimer’s disease.
Namendais(memantine) believed to work by regulating glutamate, an important brain chemical. When produced in excessive amounts, glutamate may lead to brain cell death. Because NMDA antagonists work differently from cholinesterase inhibitors, the two types of drugs can be prescribed in combination.
Many new products are known to be useful in treating Alzheimer’s disease. Such as J-147 powder, CMS121 powder.

Antiaging powder products

J-147 powder(1146963-51-0): J147 is something of a modern elixir of life,it’s been shown to treat Alzheimer’s disease and reverse aging in mice and is almost ready for clinical trials in humans.The team is already performing additional studies on the molecules that are altered by J147’s effect on the mitochondrial ATP synthase—which could themselves be new drug targets. J147 has completed the FDA-required toxicology testing in animals.
Alpha-lipoic acid powder(1077-28-7): Alpha-lipoic acid is a vitamin-like chemical called an antioxidant,which means that it might provide protection to the brain under conditions of damage or injury.
Alpha-lipoic acid seems to help prevent certain kinds of cell damage in the body, and also restores vitamin levels such as vitamin E and vitamin C. There is also evidence that alpha-lipoic acid can improve the function and conduction of neurons in diabetes.
Memory loss is a common concern among older adults.It’s believed that damage from oxidative stress plays a critical role in memory loss.
Because alpha-lipoic acid is a powerful antioxidant, studies have examined its ability to slow the progression of disorders characterized by memory loss, such as Alzheimer’s disease.
Yeast, liver, kidney, spinach, broccoli, and potatoes are good sources of alpha-lipoic acid.
CMS121 powder(1353224-53-9): Geroprotectors are substances which have the potential to slow down the rate at which an animal ages by targeting the aging processes. The new study examines a number of compounds and identifies some that protect the neurons from harm by slowing down an aging process; the researchers named these compounds geroneuroprotectors.
By using these compounds as a basis, the researchers created three Alzheimer’s drug candidates called CMS121, CAD31, and J147; they also used fisetin and curcumin directly. The team demonstrated that all five of these compounds reduced biomarkers of aging, increased the median lifespan of mice and flies, and reduced the signs of dementia.

Occurrence of aging

Aging is the impact of time on the human body, and it occurs on multiple levels:
-Cellular aging. Cells age based on the number of times they have replicated. A cell can replicate about 50 times before the genetic material is no longer able to be copied accurately, which is due to shortened telomeres. The more damage done to cells by free radicals and other factors, the more cells need to replicate.
-Hormonal aging. Hormones play a huge factor in aging, especially during childhood growth and adolescent maturity. Hormone levels fluctuate through life. Puberty brings acne and larger pores. As we get older, hormonal changes lead to dry skin and menopause.
-Accumulated damage. Accumulated damage is all external. Exposure to toxins, the sun, harmful foods, pollution, and smoke take a toll on the body. Over time, these external factors can lead to tissue damage and the body falls behind in its ability to maintain and repair cells, tissues, and organs.
-Metabolic aging. As you go about your day, your cells are constantly turning food into energy, which produces byproducts that can be harmful. The process of metabolizing and creating energy results in damage to the body over time. Some believe that slowing down the metabolic process through practices such as calorie restriction may slow aging in humans.
Common behavioral symptoms of Alzheimer’s include sleeplessness, wandering, agitation, anxiety, aggression, restlessness, and depression. Scientists are learning why these symptoms occur and are studying new treatments—drug and nondrug—to manage them.

Reference:

  1. Mortimer RK, Johnston JR (1959). “Life Span of Individual Yeast Cells”. Nature. 183 (4677): 1751–1752. Bibcode:1959Natur.183.1751M. doi:10.1038/1831751a0. hdl:2027/mdp.39015078535278. PMID 13666896
  2. Experimental drug targeting Alzheimer’s disease shows anti-aging effects” (Press release). Salk Institute. 12 November 2015. Retrieved November 13, 2015.
  3. Researchers identify the molecular target of J147, which is nearing clinical trials to treat Alzheimer’s disease”. Retrieved 2018-01-30.
  4. Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature Peter T. Nelson, Irina Alafuzoff, Eileen H. Bigio, Constantin Bouras, Heiko Braak, Nigel J. Cairns, Rudolph J. Castellani, Barbara J. Crain, Peter Davies, Kelly Del Tredici, Charles Duyckaerts, Matthew P. Frosch, Vahram Haroutunian, Patrick R. Hof, Christine M. Hulette, Bradley T. Hyman, Takeshi Iwatsubo, Kurt A. Jellinger, Gregory A. Jicha, Enikö Kövari, Walter A. Kukull, James B. Leverenz, Seth Love, Ian R. Mackenzie, David M. Mann, Eliezer Masliah, Ann C. McKee, Thomas J. Montine, John C. Morris, Julie A. Schneider, Joshua A. Sonnen, Dietmar R. Thal, John Q. Trojanowski, Juan C. Troncoso, Thomas Wisniewski, Randall L. Woltjer, Thomas G. Beach J Neuropathol Exp Neurol. Author manuscript; available in PMC 2013 Jan 30. Published in final edited form as: J Neuropathol Exp Neurol. 2012 May; 71(5): 362–381. doi: 10.1097/NEN.0b013e31825018f7